• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.

作者信息

Bouligny Ian M, Murray Graeme, Ho Thuy, Doyel Michael, Patel Tilak, Boron Josh, Tran Valerie, Gor Juhi, Hang Yiwei, Alnimer Yanal, Zacholski Kyle, Venn Chad, Wages Nolan A, Grant Steven, Maher Keri R

机构信息

Virginia Commonwealth University Massey Cancer Center - NCI Designated Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, 1001 E. Leigh St., Richmond, VA, USA.

Virginia Commonwealth University School of Medicine, 1201 E. Marshall St., Richmond, VA, USA.

出版信息

Leuk Res. 2023 Nov;134:107370. doi: 10.1016/j.leukres.2023.107370. Epub 2023 Aug 16.

DOI:10.1016/j.leukres.2023.107370
PMID:37659346
Abstract
摘要

相似文献

1
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.维奈克拉联合地西他滨或阿扎胞苷简化方案治疗急性髓系白血病
Leuk Res. 2023 Nov;134:107370. doi: 10.1016/j.leukres.2023.107370. Epub 2023 Aug 16.
2
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
3
Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?维奈克拉联合去甲基化药物治疗两名老年急性髓系白血病患者的长期疗效：是否到了采用治疗中断策略的时候？
Ann Hematol. 2024 May;103(5):1787-1788. doi: 10.1007/s00277-024-05700-4. Epub 2024 Mar 9.
4
Toward an improved understanding of hypomethylating agent and venetoclax therapies.旨在更好地理解去甲基化药物和维奈托克疗法。
Am J Hematol. 2024 Feb;99(2):152-154. doi: 10.1002/ajh.27178. Epub 2023 Dec 15.
5
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.一项在门诊环境中进行的 Venetoclax 联合阿扎胞苷或地西他滨治疗急性髓系白血病患者的 3b 期研究。
Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274.
6
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.地西他滨和西扎珠苷加维奈克拉的全口服方案：老年或身体状况不佳的急性髓系白血病患者的新进展。
Lancet Haematol. 2024 Apr;11(4):e245-e246. doi: 10.1016/S2352-3026(24)00060-7. Epub 2024 Mar 4.
7
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病：来自单中心的病例系列。
J BUON. 2021 Sep-Oct;26(5):2026-2032.
8
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.评价维奈托克联合阿扎胞苷、地西他滨或低剂量阿糖胞苷治疗急性髓系白血病的疗效。
Expert Rev Hematol. 2021 May;14(5):407-417. doi: 10.1080/17474086.2021.1938533. Epub 2021 Jun 15.
9
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.新诊断成人急性髓系白血病诱导治疗中联合低甲基化药物与标准 7+3 方案的临床状态比较。
Expert Rev Hematol. 2023 Jul-Dec;16(10):761-771. doi: 10.1080/17474086.2023.2256472. Epub 2023 Sep 8.
10
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.低甲基化药物联合维奈托克治疗急性髓系白血病：临床试验数据更新及实际应用注意事项。
Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.

引用本文的文献

1
Venetoclax combined with azacitidine in elderly acute myeloid leukemia: A retrospective comparison of 14-day vs 28-day dosing regimens.维奈托克联合阿扎胞苷治疗老年急性髓系白血病：14天与28天给药方案的回顾性比较
Medicine (Baltimore). 2025 Aug 15;104(33):e43979. doi: 10.1097/MD.0000000000043979.